Evaluation of adherence to quality measures for prostate cancer radiotherapy in the United States: Results from the Quality Research in Radiation Oncology (QRRO) Survey

Practical Radiation Oncology

Volumn 3, Issue 1, 2013, Pages 2-8

  Zelefsky, Michael J ^a   Lee, W Robert ^b   Zietman, Anthony ^c   Khalid, Najma ^d   Crozier, Cheryl ^d   Owen, Jean ^d   Wilson, J Frank ^e  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d AMERICAN COLLEGE OF RADIOLOGY   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; ATTITUDE TO HEALTH; BRACHYTHERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESEARCH; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL INDICATOR; CONTROLLED STUDY; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT ATTITUDE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE DISTRIBUTION; RADIATION EXPOSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT PLANNING; UNITED STATES;

EID: 84872039170     PISSN: 18798500     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.prro.2012.01.006     Document Type: Article

References (25)

1. Institute of Medicine Crossing the quality chasm: A new health system for the 21st century 2001, National Academy Press, Washington DC.
2. Institute of Medicine Ensuring Quality Cancer Care 1999, National Academy Press, Washington, DC. M. Hewitt, J.L. Simone (Eds.).
3. McGlynn EA, Malin J Selecting National Goals and Core Measures of Cancer Care Quality, report to Steering Committee on Cancer National Quality Forum 2002.
4. Hanks GE, Teshima T, Pajak TF 20 years of progress in radiation oncology. Prostate cancer. Semin Radiat Oncol 1997, 7:114-120.
5. Thomas GM. Over 20 years of progress in radiation oncology: Seminoma. Semin Radiat Oncol 1997, 7:135-145.
6. Enhancing Data Systems to Improve the Quality of Cancer Care. Institute of Medicine and Commission on Life Sciences 2000, 18-37. National Academy Press, Washington, DC. M. Hewitt, J.V. Simone (Eds.).
7. Earle CC, Emmanuel EJ Patterns of care studies: Creating "an environment of watchful concern". J Clin Oncol 2003, 21:4479-4480.
8. National Comprehensive Cancer Network (NCCN). Clinical practice guidelines in oncology: Prostate cancer. Version 2.2007. Available at: Accessed February 22, 2012. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
9. Crozier C, Erickson-Wittmann B, Movsas B, Owen J, Khalid N, Wilson JF Shifting the focus to practice quality improvement in radiation oncology. J Healthc Qual 2011, 33:49-57.
10. QRRO Genitourinary Committee. QRRO Clinical Performance Measures. Available at: Accessed January 4, 2012. http://www.qrro.org/Prostate_CPM.pdf.
11. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002, 53:1097-1105.
12. Zietman AL, Bae K, Slater JD, et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J Clin Oncol 2010, 28:1106-1111.
13. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006, 24:1990-1996.
14. Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8:475-487.
15. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005, 61:1285-1290.
16. Bolla M, Collette L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomized trial. Lancet 2002, 360:103-106.
17. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001, 50:1243-1252.
18. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003, 21:3972-3978.
19. Roach M III, Desilvio M, Lawton C, et al. Phase III trial comparing whole pelvic versus prostate only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003, 21:1904-1911.
20. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer. JAMA 2004, 292:821-827.
21. Jones CU, Hunt D, McGowan DG, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011, 365:107-118.
22. Zelefsky MJ, Moughan J, Owen J, Zietman AL, Roach M III, Hanks GE Changing trends in national practice for external beam radiotherapy for clinically localized prostate cancer: 1999 patterns of care survey for prostate cancer. Int J Radiat Oncol Biol Phys 2004, 59:1053-1061.
23. Nguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol 2011, 29:1517-1524.
24. Michalski H, Gay H, Jackson A, et al. Radiation dose-volume effects in radiation-induced rectal injury. Int J Radiat Oncol Biol Phys 2010, 76(suppl):S123-S129.
25. Crook JM, Potter L, Stock RG, Zelefsky MJ Critical organ dosimetry in permanent seed prostate brachytherapy: Defining the organs at risk. Brachytherapy 2005, 4:186-194.